Mutual of America Capital Management LLC Buys 67,122 Shares of Illumina, Inc. (NASDAQ:ILMN)

Mutual of America Capital Management LLC lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 278.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 91,205 shares of the life sciences company’s stock after acquiring an additional 67,122 shares during the period. Mutual of America Capital Management LLC owned 0.06% of Illumina worth $9,520,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in ILMN. Trivant Custom Portfolio Group LLC raised its position in shares of Illumina by 166.7% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 200 shares of the life sciences company’s stock worth $27,000 after acquiring an additional 125 shares in the last quarter. Versant Capital Management Inc grew its stake in Illumina by 292.9% during the 2nd quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company’s stock worth $34,000 after buying an additional 246 shares during the last quarter. Industrial Alliance Investment Management Inc. purchased a new position in Illumina during the 2nd quarter worth $34,000. Massmutual Trust Co. FSB ADV raised its stake in Illumina by 86.8% in the first quarter. Massmutual Trust Co. FSB ADV now owns 284 shares of the life sciences company’s stock valued at $39,000 after buying an additional 132 shares during the last quarter. Finally, Principal Securities Inc. purchased a new stake in Illumina in the fourth quarter valued at about $51,000. 89.42% of the stock is owned by institutional investors.

Illumina Trading Up 0.6 %

NASDAQ ILMN opened at $130.97 on Thursday. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $148.19. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market cap of $20.86 billion, a price-to-earnings ratio of -16.07 and a beta of 1.15. The firm’s 50 day moving average price is $124.62 and its two-hundred day moving average price is $120.62.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 6th. The life sciences company reported $0.36 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.24. The firm had revenue of $1.11 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Illumina had a negative net margin of 68.73% and a positive return on equity of 3.08%. The company’s quarterly revenue was down 5.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.32 EPS. Equities analysts anticipate that Illumina, Inc. will post 3.62 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ILMN. TD Cowen upgraded Illumina from a “hold” rating to a “buy” rating and increased their price target for the company from $126.00 to $144.00 in a research note on Wednesday, August 14th. Daiwa America upgraded Illumina to a “strong-buy” rating in a research note on Friday, August 16th. Barclays upgraded Illumina from an “underweight” rating to an “equal weight” rating and set a $125.00 price target for the company in a research note on Wednesday, August 14th. Piper Sandler decreased their price target on Illumina from $200.00 to $195.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Finally, Stephens reissued an “overweight” rating and issued a $170.00 price objective on shares of Illumina in a report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $151.05.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.